Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus

Priscilla Lamendola, Roberto Nerla, Dario Pitocco, Angelo Villano, Giuseppe Scavone, Alessandra Stazi, Giulio Russo, Antonino Di Franco, Alfonso Sestito, Giovanni Ghirlanda, Gaetano A. Lanza, Filippo Crea

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: To assess the effect of ranolazine on systemic vascular function in patients with type II diabetes mellitus (T2DM). Methods: We randomized 30 consecutive T2DM patients with no evidence of cardiovascular disease and no insulin therapy to receive one of the following 3 forms of treatment in a blinded fashion: ranolazine, 375 mg bid for 3 weeks (group 1); ranolazine, 375 mg bid for 2 weeks, followed by placebo bid for 1 week (group 2); placebo bid for 3 weeks (group 3). Flow-mediated dilation (FMD) and nitrate-mediated dilation (NMD) of the right brachial artery were assessed at baseline and after 48 h, and 2 and 3 weeks. Results: FMD and NMD were similar among groups at baseline. Compared to the basal value, FMD significantly improved after 2 weeks in group 1 and in group 2 (p <0.01 for both), but not in group 3. At 3 weeks, FMD remained improved, compared to baseline, in group 1 (p <0.05), whereas returned to basal values in group 2 (p = 0.89 vs. baseline). No changes in NMD were observed in any group. Conclusions: In this controlled study, ranolazine was able to improve endothelial function in T2DM patients.

Original languageEnglish
Pages (from-to)157-160
Number of pages4
JournalAtherosclerosis
Volume226
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Type 2 Diabetes Mellitus
Dilatation
Nitrates
Placebos
Brachial Artery
Ranolazine
Blood Vessels
Cardiovascular Diseases
Insulin
Therapeutics

Keywords

  • Endothelial function
  • Ranolazine
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lamendola, P., Nerla, R., Pitocco, D., Villano, A., Scavone, G., Stazi, A., ... Crea, F. (2013). Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus. Atherosclerosis, 226(1), 157-160. https://doi.org/10.1016/j.atherosclerosis.2012.10.051

Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus. / Lamendola, Priscilla; Nerla, Roberto; Pitocco, Dario; Villano, Angelo; Scavone, Giuseppe; Stazi, Alessandra; Russo, Giulio; Di Franco, Antonino; Sestito, Alfonso; Ghirlanda, Giovanni; Lanza, Gaetano A.; Crea, Filippo.

In: Atherosclerosis, Vol. 226, No. 1, 01.2013, p. 157-160.

Research output: Contribution to journalArticle

Lamendola, P, Nerla, R, Pitocco, D, Villano, A, Scavone, G, Stazi, A, Russo, G, Di Franco, A, Sestito, A, Ghirlanda, G, Lanza, GA & Crea, F 2013, 'Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus', Atherosclerosis, vol. 226, no. 1, pp. 157-160. https://doi.org/10.1016/j.atherosclerosis.2012.10.051
Lamendola, Priscilla ; Nerla, Roberto ; Pitocco, Dario ; Villano, Angelo ; Scavone, Giuseppe ; Stazi, Alessandra ; Russo, Giulio ; Di Franco, Antonino ; Sestito, Alfonso ; Ghirlanda, Giovanni ; Lanza, Gaetano A. ; Crea, Filippo. / Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus. In: Atherosclerosis. 2013 ; Vol. 226, No. 1. pp. 157-160.
@article{8221796ed09749c2ba119bca627fd7b8,
title = "Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus",
abstract = "Objective: To assess the effect of ranolazine on systemic vascular function in patients with type II diabetes mellitus (T2DM). Methods: We randomized 30 consecutive T2DM patients with no evidence of cardiovascular disease and no insulin therapy to receive one of the following 3 forms of treatment in a blinded fashion: ranolazine, 375 mg bid for 3 weeks (group 1); ranolazine, 375 mg bid for 2 weeks, followed by placebo bid for 1 week (group 2); placebo bid for 3 weeks (group 3). Flow-mediated dilation (FMD) and nitrate-mediated dilation (NMD) of the right brachial artery were assessed at baseline and after 48 h, and 2 and 3 weeks. Results: FMD and NMD were similar among groups at baseline. Compared to the basal value, FMD significantly improved after 2 weeks in group 1 and in group 2 (p <0.01 for both), but not in group 3. At 3 weeks, FMD remained improved, compared to baseline, in group 1 (p <0.05), whereas returned to basal values in group 2 (p = 0.89 vs. baseline). No changes in NMD were observed in any group. Conclusions: In this controlled study, ranolazine was able to improve endothelial function in T2DM patients.",
keywords = "Endothelial function, Ranolazine, Type 2 diabetes mellitus",
author = "Priscilla Lamendola and Roberto Nerla and Dario Pitocco and Angelo Villano and Giuseppe Scavone and Alessandra Stazi and Giulio Russo and {Di Franco}, Antonino and Alfonso Sestito and Giovanni Ghirlanda and Lanza, {Gaetano A.} and Filippo Crea",
year = "2013",
month = "1",
doi = "10.1016/j.atherosclerosis.2012.10.051",
language = "English",
volume = "226",
pages = "157--160",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus

AU - Lamendola, Priscilla

AU - Nerla, Roberto

AU - Pitocco, Dario

AU - Villano, Angelo

AU - Scavone, Giuseppe

AU - Stazi, Alessandra

AU - Russo, Giulio

AU - Di Franco, Antonino

AU - Sestito, Alfonso

AU - Ghirlanda, Giovanni

AU - Lanza, Gaetano A.

AU - Crea, Filippo

PY - 2013/1

Y1 - 2013/1

N2 - Objective: To assess the effect of ranolazine on systemic vascular function in patients with type II diabetes mellitus (T2DM). Methods: We randomized 30 consecutive T2DM patients with no evidence of cardiovascular disease and no insulin therapy to receive one of the following 3 forms of treatment in a blinded fashion: ranolazine, 375 mg bid for 3 weeks (group 1); ranolazine, 375 mg bid for 2 weeks, followed by placebo bid for 1 week (group 2); placebo bid for 3 weeks (group 3). Flow-mediated dilation (FMD) and nitrate-mediated dilation (NMD) of the right brachial artery were assessed at baseline and after 48 h, and 2 and 3 weeks. Results: FMD and NMD were similar among groups at baseline. Compared to the basal value, FMD significantly improved after 2 weeks in group 1 and in group 2 (p <0.01 for both), but not in group 3. At 3 weeks, FMD remained improved, compared to baseline, in group 1 (p <0.05), whereas returned to basal values in group 2 (p = 0.89 vs. baseline). No changes in NMD were observed in any group. Conclusions: In this controlled study, ranolazine was able to improve endothelial function in T2DM patients.

AB - Objective: To assess the effect of ranolazine on systemic vascular function in patients with type II diabetes mellitus (T2DM). Methods: We randomized 30 consecutive T2DM patients with no evidence of cardiovascular disease and no insulin therapy to receive one of the following 3 forms of treatment in a blinded fashion: ranolazine, 375 mg bid for 3 weeks (group 1); ranolazine, 375 mg bid for 2 weeks, followed by placebo bid for 1 week (group 2); placebo bid for 3 weeks (group 3). Flow-mediated dilation (FMD) and nitrate-mediated dilation (NMD) of the right brachial artery were assessed at baseline and after 48 h, and 2 and 3 weeks. Results: FMD and NMD were similar among groups at baseline. Compared to the basal value, FMD significantly improved after 2 weeks in group 1 and in group 2 (p <0.01 for both), but not in group 3. At 3 weeks, FMD remained improved, compared to baseline, in group 1 (p <0.05), whereas returned to basal values in group 2 (p = 0.89 vs. baseline). No changes in NMD were observed in any group. Conclusions: In this controlled study, ranolazine was able to improve endothelial function in T2DM patients.

KW - Endothelial function

KW - Ranolazine

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84871374278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871374278&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2012.10.051

DO - 10.1016/j.atherosclerosis.2012.10.051

M3 - Article

VL - 226

SP - 157

EP - 160

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -